FDA published the final guidance for industry, Clinical Pharmacology Considerations for Antibody-Drug Conjugates, and recently published accompaniments to the guidance document:
USA – Clinical Pharmacology Considerations for Antibody-Drug Conjugates – Final Guidance for Industry
